logo
AI Icon𝛼SK or Search
bullish

Alebund Pharmaceuticals Jiangsu

Alebund (礼邦医药) Pre-IPO: AP301 Competitive Landscape and AP306 New Global Partner

156 Views18 May 2026 16:35
Alebund is seeking to raise at least USD 100 million via a Hong Kong listing. In this note, we look at pipeline updates and the AP306-R1 Therapeutics licensing agreement since its last filing.
What is covered in the Full Insight:
  • Introduction
  • Previous Coverage on Alebund
  • Pipeline Updates
  • Updated Thoughts on Competition
  • Summary
Logo
Ke Yan, CFA, FRM
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x